{"id":"W4417466987","doi":"10.1159/000549955","title":"Early Safety Results from the Phase 3b SIERRA Study of Durvalumab and Tremelimumab as First-Line Treatment for Participants with Unresectable Hepatocellular Carcinoma and a Poor Prognosis","year":2025,"lang":"en","type":"article","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"Durvalumab; Tremelimumab; Hepatocellular carcinoma; Phases of clinical research; Ramucirumab; Chemoradiotherapy; Carcinoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005940027,0.0008711208,0.001346453,0.0002489739,0.0004713473,0.00101483,0.0007901682,0.0009176544,0.005334135],"category_scores_gemma":[0.004673198,0.0005079594,0.001754497,0.0002827767,0.0004679305,0.000762936,0.0005246711,0.002327075,0.00125289],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006858178,"about_ca_system_score_gemma":0.00159206,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006284926,"about_ca_topic_score_gemma":0.002552075,"domain_scores_codex":[0.9981576,0.001125214,0.00009232961,0.0002044926,0.000267985,0.0001524819],"domain_scores_gemma":[0.9954918,0.001070414,0.001396525,0.0004476029,0.0005778007,0.001015855],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.846194,0.01023066,0.03349121,0.00160147,0.005137609,0.0002077846,0.0002670246,0.001104244,0.01663105,0.0003992069,0.01633416,0.06840156],"study_design_scores_gemma":[0.6242553,0.2211181,0.1234829,0.0002315886,0.005422343,0.000753388,0.0001251854,0.001379706,0.005916228,0.0006762724,0.01653619,0.0001029178],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9606959,0.00689229,0.001655548,0.001568145,0.0002190201,0.004219023,0.0163818,0.0003676711,0.008000668],"genre_scores_gemma":[0.974833,0.001411574,0.002644035,0.001664802,0.0002206253,0.003746109,0.01278128,0.00006195953,0.002636529],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005940027,"threshold_uncertainty_score":0.03141421,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09119294205123218,"score_gpt":0.3126555805677392,"score_spread":0.221462638516507,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}